This clinical trial is focused on studying the effects of chemotherapy before surgery in patients with a type of cancer called retroperitoneal sarcoma. This cancer occurs in the area behind the abdominal organs. The study specifically looks at two subtypes of this cancer: leiomyosarcoma and liposarcoma. The treatment being tested involves using chemotherapy drugs such as ifosfamide, dacarbazine, epirubicin hydrochloride, and doxorubicin hydrochloride. These drugs are given through a vein, which is known as intravenous use.

The purpose of the study is to see if giving chemotherapy before surgery can improve the chances of the cancer not coming back after surgery. Patients will be randomly assigned to receive either chemotherapy followed by surgery or surgery alone. The study will last for several years, and patients will be monitored for their health and any signs of cancer returning. The main focus is on how long patients remain free of cancer after treatment, which is called disease-free survival. Other aspects being studied include overall survival, the response of the cancer to the chemotherapy, and any side effects from the treatment.

Participants in the study will undergo various tests and procedures, including imaging tests like MRI and CT scans, to assess the size and spread of the cancer. These tests help doctors determine if the cancer can be surgically removed. The study aims to gather information that could help improve treatment strategies for patients with high-risk retroperitoneal sarcoma, potentially leading to better outcomes and quality of life.